Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

IDRA Stock - Idera Pharmaceuticals Stock Trading


home / stock / idra

IDRA IDRA Quote IDRA Short IDRA News IDRA Articles IDRA Message Board

MWN AI Summary *

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) is a biopharmaceutical company focused on developing novel therapies for cancer and rare diseases. Founded in 2004 and headquartered in Wilmington, Delaware, Idera specializes in the discovery and development of Toll-like receptor (TLR) agonists and is advancing its proprietary platforms, including its focused RNA-targeting technology.

Idera's lead clinical candidate is IMO-2055, a TLR9 agonist which is being evaluated primarily for its potential to enhance the efficacy of existing cancer therapies. The company is exploring its applications in the treatment of various solid tumors, including squamous cell carcinoma of the head and neck (SCCHN). In addition to IMO-2055, Idera has several other pipeline candidates targeting unique aspects of the immune response, showcasing its commitment to addressing unmet medical needs in oncology.

The company has gained attention due to its innovative approach to harnessing the body's immune system to fight cancer. This strategy aligns with the broader trend in oncology towards immunotherapy, making Idera a player of interest in the biopharmaceutical space. As of late 2023, the company has been actively engaging in clinical trials, aiming to generate data that can support regulatory submissions and partnerships.

Idera's financial position has been bolstered through capital raises and strategic collaborations, enhancing its ability to fund ongoing research and development initiatives. However, like many biotechnology firms, it operates in a volatile market that can be influenced by clinical trial results and regulatory outcomes.

Investors remain cautiously optimistic about Idera's prospects, watching closely its advancements in clinical trials and the potential for successful product candidates to navigate the complex pharmaceutical approval landscape. Overall, Idera Pharmaceuticals stands as a notable entity within the dynamic biotech industry, seeking to leverage innovative therapies to transform patient outcomes.

MWN AI Analysis *

As of October 2023, Idera Pharmaceuticals Inc. (NASDAQ: IDRA) has shown significant potential in the biopharmaceutical sector, particularly in the development of innovative therapies for cancers and autoimmune diseases. The company focuses on advancing its proprietary immune-oncology platforms, including its lead candidate, which targets the treatment of solid tumors.

Investors should closely monitor Idera’s progress in clinical trials, particularly those undergoing Phase 2 studies. The outcomes of these trials will be crucial in determining the future trajectory of its stock. Strong efficacy and safety results could position Idera as a serious player in the competitive biotech landscape, driving stock prices upward.

Analysts suggest keeping an eye on Idera’s collaborations and partnerships, as strategic alliances with larger pharmaceutical firms can enhance research capabilities and expedite the drug development process. Additionally, any announcements regarding new partnerships or funding would signal confidence in its pipeline and could boost investor sentiment.

Moreover, considering the volatile nature of biotech investments, it’s essential to evaluate the risk-reward balance carefully. Investors should assess Idera's financial health, particularly its cash reserves and burn rate, to gauge how long it can sustain its operations and R&D before needing additional financing. As of the latest reports, the company has sufficient runway to advance its current projects but will need to communicate a clear path to profitability to sustain investor interest.

In the context of market trends, sentiment toward biotech has fluctuated due to broader economic conditions and regulatory environments. It is advisable to adopt a cautious approach, considering potential market corrections or volatility. Long-term investors may benefit from accumulating shares during price dips, while short-term investors should be prepared for potential price swings based on trial results and news flow. Overall, Idera Pharmaceuticals presents an intriguing opportunity for those who are willing to embrace the inherent risks associated with biotech investing.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Idera Pharmaceuticals Inc. (NASDAQ:IDRA)

None

Quote | Idera Pharmaceuticals Inc. (NASDAQ:IDRA)

Last:$0.425
Change Percent: 12.01%
Open:$0.4768
Close:$0.425
High:$0.51
Low:$0.42
Volume:366,686
Last Trade Date Time:01/17/2023 03:40:41 pm

News | Idera Pharmaceuticals Inc. (NASDAQ:IDRA)

  • Idera Pharma slips ahead of reverse stock split

    Rare-disease-focused nano-cap biotech Idera Pharmaceuticals ( NASDAQ: IDRA ) fell ~22% on Tuesday after the company said that a 1-for-17 reverse stock split of its common stock would take effect when the market opens on January 18, 2023. Concurrently, Exton, Pennsylvania-based Ide...

    • January 17, 2023 03:11:22 pm

    • |
    • SeekingAlpha
    • |
      • IDRA Stock
      • IDRA Quote
      • IDRA Short
      • IDRA News
      • IDRA Articles
      • IDRA Message Board
  • Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

    Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...

    • January 17, 2023 08:00:00 am

    • |
    • GlobeNewswire
    • |
      • IDRA Stock
      • IDRA Quote
      • IDRA Short
      • IDRA News
      • IDRA Articles
      • IDRA Message Board

Message Board Posts | Idera Pharmaceuticals Inc. (NASDAQ:IDRA)

Subject By Source When
znewcar1: $ACGN 87% v16,0M c3.11 f8,423M H5.37 ML1.51 znewcar1 investorshangout 05/04/2023 3:38:30 AM
$IDRA Idera Pharmaceuticals Inc mick investorshub 04/30/2023 9:21:14 PM
$IDRA Idera Pharmaceuticals Inc mick investorshub 04/15/2023 3:35:21 PM
$IDRA Idera Pharmaceuticals Inc mick investorshub 02/27/2023 12:32:32 AM
$IDRA Idera Pharmaceuticals Inc mick investorshub 02/21/2023 10:41:02 PM

MWN AI FAQ **

What recent developments or clinical trial results have impacted the stock performance of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) in 2023?

In 2023, Idera Pharmaceuticals Inc.'s stock performance was significantly influenced by the disappointing results from its clinical trial for the cancer treatment candidate, leading to increased volatility and a decline in investor confidence.

How does the pipeline of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) compare to its competitors in the biotechnology sector?

Idera Pharmaceuticals Inc.'s pipeline, focusing on innovative immune-oncology and genetic medicine therapies, is competitive but faces challenges due to the advanced research stages and market presence of larger biotechnology firms in the sector.

What are the key financial metrics to watch for Idera Pharmaceuticals Inc. (NASDAQ: IDRA) over the next quarterly earnings report?

Key financial metrics to monitor for Idera Pharmaceuticals Inc. (NASDAQ: IDRA) in the upcoming quarterly earnings report include revenue growth, R&D expenses, net loss, cash burn rate, and any updates on ongoing clinical trials and partnerships.

How has Idera Pharmaceuticals Inc. (NASDAQ: IDRA) performed in terms of partnerships or collaborations with larger pharmaceutical companies recently?

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) has made strides in recent collaborations, notably entering into partnerships that enhance its research capabilities and expand its reach in the pharmaceutical market, though specific details on recent agreements may vary.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get IDRA Alerts

News, Short Squeeze, Breakout and More Instantly...

Idera Pharmaceuticals Inc. Company Name:

IDRA Stock Symbol:

NASDAQ Market:

12.01% G/L:

$0.425 Last:

366,686 Volume:

$0.4768 Open:

$0.425 Close:

Idera Pharmaceuticals Inc. Website:

Idera Pharmaceuticals Inc. Logo

Ad

Investor Relations
RECENT IDRA NEWS
  • IDRA - Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

    Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get IDRA Alerts

Get IDRA Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1